Advanced search×

European Neuropsychopharmacology

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Sciencedirect, Gale, Ingenta, CSA, Rcgp, and Proquest

  1. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analy...

    European Neuropsychopharmacology 24(11):1719 (2014) PMID 25224106

    Our outcome was measurement of depression/depressive symptoms with a validated clinician-administered or self-rating questionnaire. PRISMA recommendations were followed and the Cochrane risk-of-bias tool used. Ten studies in 486 patients were included in the final qualitative synthesis and four stud...
  2. Title Page
    Author(s) unavailable

    European Neuropsychopharmacology 25:i (2015)

  3. Copyright
    Author(s) unavailable

    European Neuropsychopharmacology 25:ii (2015)

  4. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.

    European Neuropsychopharmacology 24(10):1698 (2014) PMID 25108314

    We recently identified ASP5736, (N-(diaminomethylene)-1-(3,5-difluoropyridin-4-yl)-4-fluoroisoquinoline-7-carboxamide (2E)-but-2-enedioate), a novel antagonist of 5-HT5A receptor, and here describe the in vitro and in vivo characterization of this compound. ASP5736 exhibited a high affinity for the...
  5. Glutamate-mediated excitotoxicity in schizophrenia: a review.

    European Neuropsychopharmacology 24(10):1591 (2014) PMID 25159198

    Findings from neuroimaging studies in patients with schizophrenia suggest widespread structural changes although the mechanisms through which these changes occur are currently unknown. Glutamatergic activity appears to be increased in the early phases of schizophrenia and may contribute to these str...
  6. The expression of contextual fear conditioning involves activation of a NMDA receptor-nitric oxide-cGMP pathway in the dorsal hippocampus of...

    European Neuropsychopharmacology 24(10):1676 (2014) PMID 25174523

    We observed a reduction of contextual fear conditioning after dorsal hippocampus administration of either the neuronal NO synthase inhibitor N-propyl-L-arginine, the NO scavenger c-PTIO or the guanylate cyclase inhibitor ODQ. Therefore, the present findings suggest the possible existence of a dorsal...
  7. The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes.

    European Neuropsychopharmacology 24(9):1492 (2014) PMID 25044051

    We investigated the effect of '523' on cognitive performance in a sample of cognitively normal Jewish elderly with type 2 diabetes, a group at particularly high risk for cognitive impairment. Using a MANCOVA procedure, we compared homozygous carriers of the S/S allele (N=179) to carriers of the VL/V...
  8. Transitions in the transcriptome of the serotonergic and dopaminergic systems in the human brain during adolescence.

    European Neuropsychopharmacology 24(7):1123 (2014) PMID 24721318

    We analyzed the mRNA expression profiles of genes that code for all components of serotonergic and dopaminergic synapses, in 16 brain areas from human and non-human primates from public domain databases, to detect genes whose expression changes during adolescence. Two serotonin receptors, HTR1E and...
  9. The effects of nicotine on cognition are dependent on baseline performance.

    European Neuropsychopharmacology 24(7):1015 (2014) PMID 24766971

    We conducted a double-blind randomised placebo-controlled crossover trial, examining the effects of placebo, 1, and 2mg of nicotine on cognition in young (n=16, age 18-30 years) and healthy elderly (n=16, age 60-75 years) subjects. We hypothesised that the elderly would benefit more from nicotine co...
  10. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.

    European Neuropsychopharmacology 24(2):251 (2014) PMID 24239329

    Tesofensine (TE) is a novel triple monoamine re-uptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine, norepinephrine, and serotonin. In recent preclinical and clinical evaluations TE showed a robust anti-obesity effect, but th...